CROSS COUNTRY HEALTHCARE INC (CCRN) Fundamental Analysis & Valuation

NASDAQ:CCRN • US2274831047

Current stock price

9.35 USD
+0.49 (+5.53%)
At close:
9.35 USD
0 (0%)
After Hours:

This CCRN fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

2

1. CCRN Profitability Analysis

1.1 Basic Checks

  • CCRN had positive earnings in the past year.
  • In the past year CCRN had a positive cash flow from operations.
  • In multiple years CCRN reported negative net income over the last 5 years.
  • In multiple years CCRN reported negative operating cash flow during the last 5 years.
CCRN Yearly Net Income VS EBIT VS OCF VS FCFCCRN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100M 200M

1.2 Ratios

  • With a Return On Assets value of -2.91%, CCRN is not doing good in the industry: 60.40% of the companies in the same industry are doing better.
  • With a Return On Equity value of -3.84%, CCRN perfoms like the industry average, outperforming 48.51% of the companies in the same industry.
  • Looking at the Return On Invested Capital, with a value of 1.10%, CCRN is doing worse than 61.39% of the companies in the same industry.
Industry RankSector Rank
ROA -2.91%
ROE -3.84%
ROIC 1.1%
ROA(3y)-4.3%
ROA(5y)5%
ROE(3y)-5.84%
ROE(5y)13.62%
ROIC(3y)N/A
ROIC(5y)N/A
CCRN Yearly ROA, ROE, ROICCCRN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 -20 40

1.3 Margins

  • CCRN has a Operating Margin of 0.56%. This is in the lower half of the industry: CCRN underperforms 61.39% of its industry peers.
  • CCRN has a Gross Margin (20.19%) which is comparable to the rest of the industry.
  • In the last couple of years the Gross Margin of CCRN has declined.
Industry RankSector Rank
OM 0.56%
PM (TTM) N/A
GM 20.19%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.25%
GM growth 5Y-3.52%
CCRN Yearly Profit, Operating, Gross MarginsCCRN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10 20

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

9

2. CCRN Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so CCRN is destroying value.
  • The number of shares outstanding for CCRN has been increased compared to 1 year ago.
  • Compared to 5 years ago, CCRN has less shares outstanding
  • CCRN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
CCRN Yearly Shares OutstandingCCRN Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M
CCRN Yearly Total Debt VS Total AssetsCCRN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M

2.2 Solvency

  • CCRN has an Altman-Z score of 4.48. This indicates that CCRN is financially healthy and has little risk of bankruptcy at the moment.
  • Looking at the Altman-Z score, with a value of 4.48, CCRN belongs to the top of the industry, outperforming 82.18% of the companies in the same industry.
  • There is no outstanding debt for CCRN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 4.48
ROIC/WACC0.12
WACC8.84%
CCRN Yearly LT Debt VS Equity VS FCFCCRN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100M 200M 300M 400M

2.3 Liquidity

  • A Current Ratio of 3.45 indicates that CCRN has no problem at all paying its short term obligations.
  • The Current ratio of CCRN (3.45) is better than 86.14% of its industry peers.
  • CCRN has a Quick Ratio of 3.45. This indicates that CCRN is financially healthy and has no problem in meeting its short term obligations.
  • CCRN's Quick ratio of 3.45 is amongst the best of the industry. CCRN outperforms 86.14% of its industry peers.
Industry RankSector Rank
Current Ratio 3.45
Quick Ratio 3.45
CCRN Yearly Current Assets VS Current LiabilitesCCRN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. CCRN Growth Analysis

3.1 Past

  • CCRN shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -95.56%.
  • The earnings per share for CCRN have been decreasing by -46.59% on average. This is quite bad
  • Looking at the last year, CCRN shows a very negative growth in Revenue. The Revenue has decreased by -21.56% in the last year.
  • The Revenue has been growing slightly by 4.74% on average over the past years.
EPS 1Y (TTM)-95.56%
EPS 3Y-84.39%
EPS 5Y-46.59%
EPS Q2Q%-250%
Revenue 1Y (TTM)-21.56%
Revenue growth 3Y-27.85%
Revenue growth 5Y4.74%
Sales Q2Q%-23.61%

3.2 Future

  • CCRN is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 128.64% yearly.
  • The Revenue is expected to decrease by -0.64% on average over the next years.
EPS Next Y388.12%
EPS Next 2Y128.64%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-5.4%
Revenue Next 2Y-0.64%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
CCRN Yearly Revenue VS EstimatesCCRN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 500M 1B 1.5B 2B 2.5B
CCRN Yearly EPS VS EstimatesCCRN Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 1 2 3 4 5

More info and screens

Find the best growth stocksShow best growing peers

4

4. CCRN Valuation Analysis

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 467.50, CCRN can be considered very expensive at the moment.
  • The rest of the industry has a similar Price/Earnings ratio as CCRN.
  • CCRN's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 25.79.
  • Based on the Price/Forward Earnings ratio of 95.78, the valuation of CCRN can be described as expensive.
  • CCRN's Price/Forward Earnings is on the same level as the industry average.
  • CCRN is valuated expensively when we compare the Price/Forward Earnings ratio to 23.80, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 467.5
Fwd PE 95.78
CCRN Price Earnings VS Forward Price EarningsCCRN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 100 200 300 400

4.2 Price Multiples

  • CCRN's Enterprise Value to EBITDA ratio is a bit cheaper when compared to the industry. CCRN is cheaper than 77.23% of the companies in the same industry.
  • Based on the Price/Free Cash Flow ratio, CCRN is valued cheaper than 92.08% of the companies in the same industry.
Industry RankSector Rank
P/FCF 6.71
EV/EBITDA 8.1
CCRN Per share dataCCRN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 10 20 30

4.3 Compensation for Growth

  • CCRN's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
  • A more expensive valuation may be justified as CCRN's earnings are expected to grow with 128.64% in the coming years.
PEG (NY)1.2
PEG (5Y)N/A
EPS Next 2Y128.64%
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. CCRN Dividend Analysis

5.1 Amount

  • No dividends for CCRN!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

CCRN Fundamentals: All Metrics, Ratios and Statistics

CROSS COUNTRY HEALTHCARE INC

NASDAQ:CCRN (3/19/2026, 4:30:02 PM)

After market: 9.35 0 (0%)

9.35

+0.49 (+5.53%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)03-04
Earnings (Next)05-05
Inst Owners84.61%
Inst Owner Change-19.96%
Ins Owners6.23%
Ins Owner Change11.36%
Market Cap306.31M
Revenue(TTM)1.05B
Net Income(TTM)-15.68M
Analysts70.67
Price Target11.6 (24.06%)
Short Float %4.29%
Short Ratio2.22
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-69.09%
Min EPS beat(2)-118.38%
Max EPS beat(2)-19.79%
EPS beat(4)1
Avg EPS beat(4)-49.67%
Min EPS beat(4)-118.38%
Max EPS beat(4)5.59%
EPS beat(8)4
Avg EPS beat(8)-23.71%
EPS beat(12)7
Avg EPS beat(12)-12.92%
EPS beat(16)11
Avg EPS beat(16)-6.6%
Revenue beat(2)0
Avg Revenue beat(2)-8.46%
Min Revenue beat(2)-9.46%
Max Revenue beat(2)-7.46%
Revenue beat(4)0
Avg Revenue beat(4)-5.87%
Min Revenue beat(4)-9.46%
Max Revenue beat(4)-0.73%
Revenue beat(8)1
Avg Revenue beat(8)-3.08%
Revenue beat(12)3
Avg Revenue beat(12)-1.76%
Revenue beat(16)6
Avg Revenue beat(16)-0.91%
PT rev (1m)-0.66%
PT rev (3m)-22.47%
EPS NQ rev (1m)-8.7%
EPS NQ rev (3m)15.38%
EPS NY rev (1m)-19.12%
EPS NY rev (3m)-24.93%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-1.34%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.49%
Valuation
Industry RankSector Rank
PE 467.5
Fwd PE 95.78
P/S 0.27
P/FCF 6.71
P/OCF 5.65
P/B 0.75
P/tB 1.29
EV/EBITDA 8.1
EPS(TTM)0.02
EY0.21%
EPS(NY)0.1
Fwd EY1.04%
FCF(TTM)1.39
FCFY14.91%
OCF(TTM)1.66
OCFY17.71%
SpS34.42
BVpS12.46
TBVpS7.25
PEG (NY)1.2
PEG (5Y)N/A
Graham Number2.37
Profitability
Industry RankSector Rank
ROA -2.91%
ROE -3.84%
ROCE 1.39%
ROIC 1.1%
ROICexc 1.41%
ROICexgc 2.72%
OM 0.56%
PM (TTM) N/A
GM 20.19%
FCFM 4.05%
ROA(3y)-4.3%
ROA(5y)5%
ROE(3y)-5.84%
ROE(5y)13.62%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.25%
GM growth 5Y-3.52%
F-Score5
Asset Turnover2.09
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 49.56%
Cap/Sales 0.76%
Interest Coverage 250
Cash Conversion 229.81%
Profit Quality N/A
Current Ratio 3.45
Quick Ratio 3.45
Altman-Z 4.48
F-Score5
WACC8.84%
ROIC/WACC0.12
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-95.56%
EPS 3Y-84.39%
EPS 5Y-46.59%
EPS Q2Q%-250%
EPS Next Y388.12%
EPS Next 2Y128.64%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-21.56%
Revenue growth 3Y-27.85%
Revenue growth 5Y4.74%
Sales Q2Q%-23.61%
Revenue Next Year-5.4%
Revenue Next 2Y-0.64%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-52.34%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year297.63%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-53.83%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-49.76%
OCF growth 3YN/A
OCF growth 5YN/A

CROSS COUNTRY HEALTHCARE INC / CCRN Fundamental Analysis FAQ

What is the ChartMill fundamental rating of CROSS COUNTRY HEALTHCARE INC (CCRN) stock?

ChartMill assigns a fundamental rating of 4 / 10 to CCRN.


What is the valuation status for CCRN stock?

ChartMill assigns a valuation rating of 4 / 10 to CROSS COUNTRY HEALTHCARE INC (CCRN). This can be considered as Fairly Valued.


Can you provide the profitability details for CROSS COUNTRY HEALTHCARE INC?

CROSS COUNTRY HEALTHCARE INC (CCRN) has a profitability rating of 2 / 10.


Can you provide the expected EPS growth for CCRN stock?

The Earnings per Share (EPS) of CROSS COUNTRY HEALTHCARE INC (CCRN) is expected to grow by 388.12% in the next year.